Forhøjelsen af ALAT var sammenlignelig hos patienter, der modtog adalimumab eller placebo i de kontrollerede kliniske forsøg for psoriasis.
Psoriasis clinical trials: in controlled psoriasis clinical trials, elevations of ALT were similar in patients receiving adalimumab or placebo.